论文部分内容阅读
自1944年以来,作者一直从事于新抗生素的研究。近三十年,抗细菌抗生素研究已在耐药生化机制基础上,扩大到发展有效的衍生物;发展了抗肿瘤抗生素及其用于癌症治疗的衍生物;开创了具有各种生理活性与药物作用的酶抑制剂。作者能为开辟这些新的令人兴奋研究领域作出贡献而感到高兴。抗生素和小分子酶抑制剂均为不参与微生物细胞生长的次级代谢产物。这些次级代谢物的研究已证明了微生物是提供治疗人和
Since 1944, the author has been engaged in the research of new antibiotics. In the past thirty years, the research on antibacterial antibiotics has expanded to develop effective derivatives based on the mechanism of drug-resistance and biochemistry, the development of anti-tumor antibiotics and their derivatives for cancer treatment, the creation of bioactive antibiotics with various physiological activities and drugs The role of enzyme inhibitors. The author is happy to contribute to these new and exciting areas of research. Antibiotics and small molecule enzyme inhibitors are secondary metabolites that are not involved in the growth of microbial cells. Studies of these secondary metabolites have demonstrated that microbes are used to treat humans and humans